The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma
Glioblastoma (GBM) is a highly aggressive brain tumor with limited treatment options and poor prognosis. Bispecific T-cell engagers (TCEs) offer a promising immunotherapy approach by redirecting T cells to tumor antigens, and this review highlights their progress and challenges in glioma treatment.